Seoul: Celltrion Inc., a leading South Korean biopharmaceutical company, announced its plan to repurchase 100 billion won (US$68 million) of its own shares. This strategic move is designed to boost shareholder value.

According to Yonhap News Agency, the buyback aims to support the company's valuation amidst external uncertainties arising from tensions in the Middle East. Celltrion highlighted this initiative in a recent press release.

In addition to the buyback, Celltrion recently cancelled treasury shares valued at 1.8 trillion won, as part of a broader strategy to return value to its shareholders. The company official emphasized their commitment to aligning corporate value with shareholder interests through consistent earnings growth and proactive policies.